Trying to get my sad tired brain around some relenza figures.
Production is expected to be 190m doses, but lets be conservative and say 170m (20m freebies) x $25 per dose = 4,250m x 7% = $298m in royalties
but the other info gsk is reporting is that they expect 600 pounds, say $1,200m x 7% = $84 mill
What am I missing? Is it the lag to ramping up production or does the new delivery method produce lower revenue? Any clues anybody?
cheers
- Forums
- ASX - By Stock
- BTA
- please explain
please explain
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online